

Audit Review Table

Presbyterian Health Plan, Inc. (Org ID: 579, SubID: 4104, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014

The Auditor lock has been applied to this submission.

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	84.35%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				43.26%	R	Reportable
<i>Counseling for Nutrition</i>				52.79%	R	Reportable
<i>Counseling for Physical Activity</i>				43.72%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				79.17%	R	Reportable
<i>IPV</i>				87.96%	R	Reportable
<i>MMR</i>				91.20%	R	Reportable
<i>HiB</i>				90.28%	R	Reportable
<i>Hepatitis B</i>				81.25%	R	Reportable
<i>VZV</i>				90.51%	R	Reportable
<i>Pneumococcal Conjugate</i>				78.01%	R	Reportable
<i>Hepatitis A</i>				87.27%	R	Reportable
<i>Rotavirus</i>				75.46%	R	Reportable
<i>Influenza</i>				53.94%	R	Reportable
<i>Combination #2</i>				69.44%	R	Reportable
<i>Combination #3</i>				64.58%	R	Reportable
<i>Combination #4</i>				61.81%	R	Reportable
<i>Combination #5</i>				56.48%	R	Reportable
<i>Combination #6</i>				39.12%	R	Reportable
<i>Combination #7</i>				54.40%	R	Reportable
<i>Combination #8</i>				38.19%	R	Reportable
<i>Combination #9</i>				35.19%	R	Reportable
<i>Combination #10</i>				34.49%	R	Reportable
Immunizations for Adolescents (ima)	Y		N			
<i>Meningococcal</i>				67.08%	R	Reportable

<i>Tdap/Td</i>				78.71%	R	Reportable
<i>Combination #1</i>				64.85%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hvp)	Y			25.00%	R	Reportable
Lead Screening in Children (lsc)	Y		N	32.87%	R	Reportable
Breast Cancer Screening (bcs)	Y			49.71%	R	Reportable
Cervical Cancer Screening (ccs)	Y			57.25%	R	Reportable
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			2.27%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
<i>16-20 Years</i>				40.35%	R	Reportable
<i>21-24 Years</i>				56.43%	R	Reportable
<i>Total</i>				46.32%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		67.58%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		86.79%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		25.94%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			26.21%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
<i>Systemic Corticosteroid</i>				45.11%	R	Reportable
<i>Bronchodilator</i>				55.74%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
<i>5-11 Years</i>				91.06%	R	Reportable
<i>12-18 Years</i>				79.41%	R	Reportable
<i>19-50 Years</i>				63.75%	R	Reportable
<i>51-64 Years</i>				53.62%	R	Reportable

<i>Total</i>				81.21%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				
<i>5-11 Years - Medication Compliance 50%</i>				45.51%	R	Reportable
<i>5-11 Years - Medication Compliance 75%</i>				21.32%	R	Reportable
<i>12-18 Years - Medication Compliance 50%</i>				40.57%	R	Reportable
<i>12-18 Years - Medication Compliance 75%</i>				18.86%	R	Reportable
<i>19-50 Years - Medication Compliance 50%</i>				51.18%	R	Reportable
<i>19-50 Years - Medication Compliance 75%</i>				27.96%	R	Reportable
<i>51-64 Years - Medication Compliance 50%</i>				56.76%	R	Reportable
<i>51-64 Years - Medication Compliance 75%</i>				27.03%	R	Reportable
<i>Total - Medication Compliance 50%</i>				44.72%	R	Reportable
<i>Total - Medication Compliance 75%</i>				21.41%	R	Reportable
Asthma Medication Ratio (amr)	Y	Y				
<i>5-11 Years</i>				62.25%	R	Reportable
<i>12-18 Years</i>				47.71%	R	Reportable
<i>19-50 Years</i>				34.14%	R	Reportable
<i>51-64 Years</i>				34.78%	R	Reportable
<i>Total</i>				51.51%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions						
Controlling High Blood Pressure (cbp)	Y			55.95%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		76.47%	R	Reportable
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
<i>Hemoglobin A1c (HbA1c) Testing</i>				86.52%	R	Reportable
<i>HbA1c Poor Control (>9.0%)</i>				43.93%	R	Reportable
<i>HbA1c Control (<8.0%)</i>				47.92%	R	Reportable
<i>HbA1c Control (<7.0%)</i>				35.22%	R	Reportable
<i>Eye Exam (Retinal) Performed</i>				47.75%	R	Reportable
<i>Medical Attention for Nephropathy</i>				79.53%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>				64.23%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions						

Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		66.67%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			75.13%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
<i>Effective Acute Phase Treatment</i>				53.94%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				38.97%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				43.33%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>				48.89%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
<i>30-Day Follow-Up</i>				67.88%	R	Reportable
<i>7-Day Follow-Up</i>				43.14%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		79.84%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			75.00%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	Denominator fewer than 30
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		58.05%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y	Y				
<i>1-5 Years</i>				NA	R	Denominator fewer than 30
<i>6-11 Years</i>				17.50%	R	Reportable
<i>12-17 Years</i>				10.87%	R	Reportable

<i>Total</i>				13.00%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y	Y				
<i>1-5 Years</i>				NA	R	Denominator fewer than 30
<i>6-11 Years</i>				35.15%	R	Reportable
<i>12-17 Years</i>				42.02%	R	Reportable
<i>Total</i>				39.41%	R	Reportable
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
<i>ACE Inhibitors or ARBs</i>				83.91%	R	Reportable
<i>Digoxin</i>				NA	R	Denominator fewer than 30
<i>Diuretics</i>				84.75%	R	Reportable
<i>Total</i>				84.00%	R	Reportable
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
<i>20-44 Years</i>				79.92%	R	Reportable
<i>45-64 Years</i>				85.82%	R	Reportable
<i>65+ Years</i>				88.39%	R	Reportable
<i>Total</i>				81.93%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
<i>12-24 Months</i>				89.51%	R	Reportable
<i>25 Months - 6 Years</i>				80.91%	R	Reportable
<i>7-11 Years</i>				90.04%	R	Reportable
<i>12-19 Years</i>				88.64%	R	Reportable
Annual Dental Visit (adv)	Y	Y				
<i>2-3 Years</i>				54.36%	R	Reportable
<i>4-6 Years</i>				73.17%	R	Reportable
<i>7-10 Years</i>				76.71%	R	Reportable
<i>11-14 Years</i>				72.61%	R	Reportable
<i>15-18 Years</i>				61.91%	R	Reportable

19-21 Years				39.34%	R	Reportable
Total				68.14%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				
Initiation of AOD Treatment: 13-17 Years				36.56%	R	Reportable
Engagement of AOD Treatment: 13-17 Years				14.99%	R	Reportable
Initiation of AOD Treatment: 18+ Years				36.70%	R	Reportable
Engagement of AOD Treatment: 18+ Years				14.02%	R	Reportable
Initiation of AOD Treatment: Total				36.69%	R	Reportable
Engagement of AOD Treatment: Total				14.14%	R	Reportable
Prenatal and Postpartum Care (ppc)	Y					
Timeliness of Prenatal Care				77.88%	R	Reportable
Postpartum Care				61.88%	R	Reportable
Call Answer Timeliness (cat)	Y			87.76%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y	Y				
1-5 Years				NA	R	Denominator fewer than 30
6-11 Years				55.81%	R	Reportable
12-17 Years				45.78%	R	Reportable
Total				49.81%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<21 Percent				13.65%	R	Reportable
21-40 Percent				12.47%	R	Reportable
41-60 Percent				12.71%	R	Reportable
61-80 Percent				12.47%	R	Reportable
81+ Percent				48.71%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		N			
0 Visits				3.89%	R	Reportable
1 Visit				2.64%	R	Reportable
2 Visits				4.44%	R	Reportable
3 Visits				7.43%	R	Reportable
4 Visits				12.87%	R	Reportable
5 Visits				22.20%	R	Reportable

6+ Visits				46.54%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	54.93%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	36.36%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	Y				R	Reportable
Ambulatory Care: Disabled (ambc)	Y				R	Reportable
Ambulatory Care: Other (ambd)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	Y				R	Reportable
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Other (iadd)	Y	Y			R	Reportable
Mental Health Utilization: Total (mpta)	Y	Y			R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y	Y			R	Reportable
Mental Health Utilization: Disabled (mptc)	Y	Y			R	Reportable
Mental Health Utilization: Other (mptd)	Y	Y			R	Reportable
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y	Y			R	Reportable
Antibiotic Utilization: Disabled (abxc)	Y	Y			R	Reportable
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected

Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable
Relative Resource Use for People With Asthma (ras)	Y	Y			R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable
Health Plan Descriptive Information						
Board Certification (bcr)	Y				R	Reportable
Total Membership (tlm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	Y				R	Reportable
Enrollment by Product Line: Disabled (enpc)	Y				R	Reportable
Enrollment by Product Line: Other (enpd)	Y				R	Reportable
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment (wop)	Y				R	Reportable